Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
复制标题
DOI：
10.1136/jitc-2022-005065
复制
发表时间：
2022
影响因子：
10.9
通讯作者：
Tingbo Liang
中科院分区：
文献类型：
--
作者：
Tianyu Tang;Xing Huang;Gang Zhang;Tingbo Liang
Oncolytic peptides are highly effective on remodeling the tumor microenvironment and potentiating the anticancer immunity through multiple mechanisms, particularly by inducing immunogenic cell death. Intriguingly, a recent study demonstrates that LTX-315, one of the most promising and extensively studied oncolytic peptides, inhibits PD-L1 expression via ATP11B, thus enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. Therefore, this commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, further highlighting the potential issues and directions of oncolytic peptides in cancer immunotherapy.
